Abstract
During the past few decades, suggestive evidence has been accumulated that abnormalities in serotonin neurotransmission are involved in the pathogenesis of aggressive behaviour disorders and impulsivity. Support for this idea can be derived from clinical studies using 5-HT1 agonistic compounds and serotonergic antidepressants. In the present study, the efficacy of the 5-HT1a agonist buspirone was investigated in eight patients with mental retardation and severe, long-lasting challenging behaviour, characterized by aggressive outbursts, self-injurious behaviour and impulsivity. The findings demonstrate that buspirone, in a daily dosage varying between 20 and 50 mg, may be effective in reducing this type of behavioural disturbance and associated with an improvement in sociability. It is hypothesized that the responsiveness to buspirone treatment may be the result of a de-arousing phenomenon, mediated via corticosteroid dependent stress homeostatic mechanisms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
